CClinicalTrials.gg
RecruitingNCT05452031Updated Jun 18, 2026

A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers

An interventional study of Care2Sleep and Sleep Education in Sleep, sponsored by University of California, Los Angeles. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
672
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized controlled trial over 5 years, using Stage II of the NIH-defined stage model for behavioral intervention development. We will evaluate the efficacy of the sleep intervention program (Care2Sleep) on sleep, health status measures, and quality of life (for dyads), and inflammation (for caregivers only). Eligible participants will be randomly assigned to in-person Care2Sleep, telehealth Care2Sleep, or to an in-person education control group. The Care2Sleep programs and the control education program will consist of five sessions. The intervention and control programs will begin after baseline assessment and randomization. Posttreatment assessments will be performed immediately after the last session and at 6-month follow-up.

02

Conditions studied

  • Sleep

Browse trials for

Keywords

  • Dementia
  • Caregivers
03

In context

Dementia

2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.

This study's planned enrollment of 672 is above the median of 83 across 1,629 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Patients

  • Have a diagnosis of Alzheimer's disease (probable or possible) or other related dementia as documented in an electronic medical record
  • Community-dwelling
  • >1 sleep problems >3x/week on the Neuropsychiatric Inventory Nighttime Behavior Scale, - - Aged >60 years
  • Have no untreated sleep disorders (e.g., sleep apnea, restless legs syndrome)
  • Able to ambulate with or without assistive devices (i.e., dyads will be excluded if the care recipient is bedbound)
  • Have no severe medical conditions with a life expectancy of less than 6 months
  • Have an eligible caregiver

Inclusion Criteria for Caregivers

  • Live with an eligible patient
  • Aged >18 years
  • Is related to the patient as a family member, a significant other, or a friend
  • Have regularly assisted patient with >1 of 6 basic activities of daily living (ADLs; i.e., bathing, dressing, toileting, transferring, continence, feeding) or >1 of 8 Instrumental ADL (IADLs; i.e., using the telephone, shopping, food preparation, housekeeping, laundry, transportation, taking medications, managing money) for the past 6 months
  • Pittsburgh Sleep Quality Index (PSQI) total score >5
  • Montreal Cognitive Assessment (MoCA) ≥23
  • Can communicate in English

Exclusion Criteria:

  • Patients will be excluded if they are bedbound or have severe medical conditions with a life expectancy of less than 6 months.
  • Paid, professional caregivers will also be excluded.
  • If the eligibility criteria for either a patient or a caregiver are not met, the dyads will be excluded for this study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
672 participants (estimated)

Study arms

  • Experimental
    In-Person Care2Sleep

    In-person, manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy

    Behavioral: Care2Sleep

  • Active comparator
    Telehealth Care2Sleep

    Telehealth, manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy

    Behavioral: Care2Sleep

  • Placebo comparator
    Sleep Education only

    In-person, education on sleep, aging, and dementia but without specific or individualized recommendations

    Behavioral: Sleep Education

Interventions

  • BehavioralCare2Sleep

    A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.

  • BehavioralSleep Education

    This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations

06

What researchers measure

Primary outcomes

  1. Sleep efficiency-Actigraphy

    Nighttime sleep efficiency (i.e., mean percent of time in bed spent asleep) will be calculated from 7 days of wrist actigraphy for patients and caregivers. Range from 0 to 100% with a higher percent indicating better objective sleep quality

    Time frame: Change from Baseline Sleep Efficiency at 6 months

  2. Pittsburgh Sleep Quality Index score

    Self-reported sleep quality over the past week for patients (reported by caregivers) and caregivers. Range from 0 to 21 with lower scores indicating better subjective sleep quality.

    Time frame: Change from Baseline Pittsburgh Sleep Quality Index score at 6 months

Secondary outcomes

  1. Total score of Revised Memory and Behavior Problem Checklist

    Dementia-related problem behaviors among persons with dementia (reported by caregivers). Range from 0 to 96 with higher scores indicating more severe dementia-related behaviors.

    Time frame: Immediately AND 6 months after the last session of the intervention

  2. Total score of Quality of Life-Alzheimer's Disease Scale

    Quality of life among persons with dementia reported by either caregivers or persons with dementia. Range from 4 to 52 with higher scores indicating better quality of life among persons with dementia

    Time frame: Immediately AND 6 months after the last session of the intervention

  3. Total score of Zarit Burden Interview

    Perceived levels of caregiving burden. Range from 0 to 88 with higher scores indicating greater burden among caregivers

    Time frame: Immediately AND 6 months after the last session of the intervention

  4. Total score of Center for Epidemiological Study of Depression Scale

    Perceived frequency of depressive symptoms during the past week. Ranges from 0 to 60 with higher scores indicating greater levels of depressive symptoms among caregivers

    Time frame: Immediately AND 6 months after the last session of the intervention

  5. Patient-Reported Outcomes Measurement Information System (PROMIS) global health score

    Self-reported physical and mental health scores among caregivers. A T-score of 50 represents the mean of the general population. Higher scores indicate better physical and mental health among caregivers

    Time frame: Immediately AND 6 months after the last session of the intervention

  6. Levels of inflammatory markers

    Three key inflammatory markers including C-reactive protein, Tumor necrosis factor-alpha, Interleukin-6 will be collected among caregivers only

    Time frame: Immediately AND 6 months after the last session of the intervention

07

Study locations

3 of 3 sites recruiting
  • University of California San Diego
    La Jolla, California 92093, United States
    Recruiting
  • University of California Los Angeles
    Los Angeles, California 90095, United States
    • Yeonsu Song, PhD · Contact
    • Yeonsu Song, PhD · Principal investigator
    Recruiting
  • Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 91343, United States
    • Yeonsu Song, PhD · Contact · 818-891-7711
    • Yeonsu Song, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Materials generated under the project will be disseminated in accordance with policies at UCLA and NIH. Data products from this study will be made available without cost to researchers, students, and analysts. The final database (both GAD and LAD) will be managed at the UCLA School of Nursing Research Office Design \& Data Core. User registration will be required through the Design \& Data Core in order to access or download files.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05452031
Lead sponsor
University of California, Los Angeles
Collaborators
University of California, San Diego, VA Greater Los Angeles Healthcare System
Responsible party
Yeonsu Song, PhD, RN, FNP (Assistant Professor, University of California, Los Angeles) — Principal investigator
First posted
Jul 11, 2022
Start date
Nov 9, 2022
Primary completion
May 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Yeonsu Song
Contact
ysong@sonnet.ucla.edu
310-983-3029

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion